



ANNUAL REPORT

Fiscal Year 2019-2020






A Letter from our Executive Director



Reflecting on the year ending June 30, 2020, one word comes to mind - resilience. In the face of a global pandemic, I am struck by the way my colleagues and my incredible staff were able to adjust to this new normal and double down on their commitment to serve those most vulnerable among us. Working in the fields of addiction and HIV, we see those people living in the margins. We also see the inequities in treatment faced by people of color that were reflected so brutally in the murder of George Floyd and too many others.

Like everyone else, our daily work lives have changed drastically. Our clinic has been rearranged and new processes implemented to keep our staff and research participants safe. Many of us have moved to remote work with video conference calls dominating our work days. While making these adjustments, we have continued to look for ways to connect to and serve our community. We are currently working with the COVID Prevention Network, enrolling participants into the Moderna vaccine trial, including a large number of people of color. We were awarded supplemental funding to address COVID within our cohort study of minority men who have sex with men. We also received funds as part of the national Ending the HIV Epidemic initiative that will be used to optimize PrEP outcomes among Black and Latina women. We continued development of new programs and are most excited to announce that, in the coming year CBAM will be going mobile! Our clinic in Hollywood has served thousands, but we know there are so many more individuals in need in other parts of Los Angeles County. And so we are in process of procuring a mobile clinic equipped with 2 exam rooms that will allow us to bring addiction treatment and HIV prevention directly to those most in danger of opioid overdose through a new research project I'm leading with the HIV Prevention Trials Network.

Thank you for your continued support on this journey. Stay safe.





Research Highlights



In pursuit of our mission, CBAM conducts research on medical, behavioral, and combination approaches to the prevention and treatment of chronic illnesses, with a particular focus on addiction and HIV. We stress the values of integrity and scientific rigor in the conduct of our research and work closely with the communities we serve to ensure that the best of care is given. The following pages highlight our research activities over the past year.





New Studies

California Bridge Patient Outcomes Research Evaluation Study



Medication assisted treatment (MAT) is an essential part of evidence-based rapid response treatment and is highly effective in acute care settings. The California Bridge Program develops hospitals and emergency rooms as primary access points for addiction treatment. This intensive program provides training and technical assistance to acute care providers to encourage patients to enter and remain in treatment. We are working in collaboration with Public Health International (PHI) on a research study related to the Bridge Program that will (1) expand the assessment battery currently being used by PHI to make it comparable to other datasets currently being compiled in the setting of providing medication assisted therapy (MAT) in emergency care settings and (2) build a cohort of participants willing to be contacted for future research opportunities to test prospective hypotheses about long-term health outcomes when providing MAT in emergency health settings.



Technology Improving Success of Medication-Assisted Treatment in Primary Care

The opioid epidemic is U.S.'s most widespread behavioral public health problem, with a higher number of deaths due to overdose in 2016 compared to deaths due to HIV at the peak of the AIDS epidemic. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious. However, only a fraction of persons with OUD access MAT and treatment non-adherence and drop out is common. There is a dire need to improve systems to address these issues and to expand the use of MAT for many patients who are out of care. This NIH-funded project is conducted in collaboration with the technology company Q2i, developer of the Opioid Addiction Recover Support platform (OARS). In Phase 1 of the study, we will conduct interviews with physicians and patients using OARS to determine the feasibility and acceptability of using the platform in a primary care setting. The platform will then be modified according to our results and we will move into a second phase to assess the effectiveness of OARS in improving opioid agonist treatment outcomes and to evaluate sustainability and return on investment.



New Collaborations

In June, CBAM joined the University of Texas Southwest Medical Center (UTSW) and the University of Texas Health Science Center at San Antonio to form the Big South/West Node of the Clinical Trials Network (CTN). The CTN is a collaboration between NIDA, treatment researchers, and community-based service providers working toward new treatment options in community-level clinical practice. The Big South/West Node's research agenda includes a focus on the fourth wave of the opioid epidemic, building upon the expertise of our investigators in treating stimulant and opioid use disorders. The team has experience with innovative study designs that target all areas of the translational science continuum in order to successfully and significantly improve the care of persons who misuse substances.



UCLA CBAM first joined with UTSW in 2016 as a clinical research site for the CTN-0068 (ADAPT-2) study, which tested the use of extended-release naltrexone plus high-dose bupropion for adults with moderate to severe methamphetamine use disorder. ADAPT-2 was the largest pharmacotherapy trial for the treatment of methamphetamine use disorder conducted to date and this new Node is already in development on exciting new research protocols to be implemented before the end of this year.

Research Results - HPTN 083



In May, we received exciting news. Results of the HPTN 083 study, showed that the long-acting injectable medication cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men. This global study included two sites in Los Angeles, our UCLA Vine Street Clinic and the UCLA CARE Center, and was led by CHIPTS Co-Director, Dr. Raphael Landovitz. While preexposure prophylaxis (PrEP) is currently available in the form of a daily pill, many of those at high risk for HIV have difficulty with the regimen. Adding more options to the prevention tool box will go a long way towards continued reductions in HIV rates for our most vulnerable populations. More information can be found [here](#).

Scientific Presentations

CBAM Faculty made presentations at several scientific conferences this year, with in-person talks spanning the globe. Before everything moved on-line, Dr. Ron Brooks presented at the American Public Health Association conference in Philadelphia and Dr. Steven Shoptaw presented to the Australian Professional Society on Alcohol and other Drugs in Hobart, Australia.





The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of leading researchers promoting collaborative research, networking, and capacity building among HIV researchers and communities in efforts to eliminate new HIV infections and health disparities among key populations with HIV-associated comorbidities.

This year, CHIPTS was awarded three one-year grants by the National Institute of Mental Health totaling \$395,000. As part of the national [Ending the HIV Epidemic](#) initiative, these projects include a regional response to HIV eradication efforts in Southern California counties, led by Dr. Shoptaw; assessment of the feasibility of using apps, telehealth, text messaging and other digital technologies to encourage the use of PrEP among men who have sex with men and transgender women of color, led by Dr. Ron Brooks; and one to lay the groundwork for the rollout of a long-acting, injectable anti-retroviral treatment, led by Dr. Raphy Landovitz. Preliminary [results](#) are currently available.

New Reports from CHIPTS

Ending the HIV Epidemic Supplement Projects



Regional Response to HIV Eradication Efforts in California Counties



Use of Technology-Based PrEP to Improve Uptake, Adherence, and Persistence



Preparing for Long-Acting Injectable Treatment for HIV in Los Angeles

assessment of the feasibility of using apps, telehealth, text messaging and other digital technologies to encourage the use of PrEP among men who have sex with men and transgender women of color, led by Dr. Ron Brooks; and one to lay the groundwork for the rollout of a long-acting, injectable anti-retroviral treatment, led by Dr. Raphy Landovitz. Preliminary [results](#) are currently available.

In November 2019, we co-hosted a conference entitled "Addressing Medical Mistrust in Black Communities: Implications for HIV and Other Conditions". More than 150 community members, providers, educators, policy makers, and stakeholders joined us to discuss improving understanding of the historical foundations of medical mistrust in Black communities; to describe the effects of medical mistrust on health care behaviors, HIV and other health outcomes in Black communities; to discuss clinic and system level changes that foster patient trust; and to provide attendees with skills and resources to interact with patients and caregivers in a manner that encourages healthcare engagement and improve health outcomes. The day's events included a key note address by Dr. Marino Bruce, Professor of Medicine, Health and Society at Mississippi State University, as well as a panel of local community members and providers.



CHIPTS awarded funding to young investigators for several pilot studies this year, including:

New Pilot Studies

Investigator

David Goodman, MD

Study Title

Developing a community informed psychosocial intervention for women who inject drugs in Mexicali, Mexico.

Alex Dubov, PhD

An exploration of primary care providers' implicit bias against substance using MSM and its impact on clinical decision-making for HIV pre-exposure prophylaxis

For more information on CHIPTS, visit the [website](#).



Scientific Publications



As scientists, our biggest impact comes from the knowledge we generate and share. It's that knowledge of what works, what doesn't and why that leads to better policy, better medicine and better lives for those we serve. This year, CBAM faculty and staff contributed to the publication of 38 peer-reviewed articles in scientific journals.

Highlights include the first round of results from our on-going collaborations with the Los Angeles County Department of Public Health's Division of HIV and STD Programs.

- Michael J. Li, Erica Su, Wendy H. Garland, Sona Oksuzyan, Sung-Jae Lee, Uyen H. Kao, Robert E. Weiss, Steven J. Shoptaw, PhD. Trajectories of viral suppression in people living with HIV receiving coordinated care: Differences by comorbidities. *Journal of Acquired Immune Deficiency Syndromes*. 2020 Aug 1;84(4):387-395.

Our international work took the spotlight this year. In addition to those listed below, see the next page for updates on our work in Cape Town, South Africa.

- Michael Farrell, Natasha K Martin, Emily Stockings, Annick Bórquez, Javier A Cepeda, Louisa Degenhardt, Robert Ali, Lucy Thi Tran, Jürgen Rehm, Marta Torrens, Steve Shoptaw, Rebecca McKetin. Responding to global stimulant use: challenges and opportunities. *The Lancet*. Vol 394, Iss 10209. 2019 November 2. p1652-1667.
- Passaro, R. C., Castañeda-Huaripata, A., Gonzales-Saavedra, W., Chavez-Gomez, S., Segura, E. R., Lake, J. E., Cabello, R., & Clark, J. L. Contextualizing condoms: a cross-sectional study mapping intersections of locations of sexual contact, partner type, and substance use as contexts for sexual risk behavior among MSM in Peru. *BMC infectious diseases*, 19(1), 958.

And we commented on importance of keeping our focus on the co-occurring epidemics of opioids, sexually transmitted infections (STIs), and HIV, among other public health concerns, while addressing COVID-19.

- Steven Shoptaw, David Goodman-Meza, Raphael J. Landovitz. Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19. *AIDS and Behavior*. 24(7): 2013–2016. 2020 Apr 16.
- To learn more and to read summaries of each article, visit our [website](#).



International Reach

South Africa

We've been working with the University of Cape Town since 20##. In addition to our on-going mentorship of junior investigators and development of new projects, we published three papers this year from our study of contingency management as treatment for methamphetamine use disorder.



- Chukwuemeka N. Okafor, Dan J. Stein, Lisa Dannatt, Jonathan Ipser, Lara J. van Nunen, Marilyn T. Lake, Tamar Krishnamurti, Edythe D. London, Steve Shoptaw. Contingency management treatment for methamphetamine use disorder in South Africa. *Drug and Alcohol Review*. March 2020, 39, 216-222.
- Tamar Krishnamurti, Kimberly Ling Murtaugh, Lara Van Nunen, Alexander L. Davis, Jonathan Ipser, Steven Shoptaw. Spending money to make change: Association of methamphetamine abstinence and voucher spending among contingency management pilot participants in South Africa. *Journal of Substance Abuse Treatment*. Volume 112, May 2020, Pages 60-67.
- Marilyn T. Lake, Steven Shoptaw, Jonathan C. Ipser, Sae Takada, Lara J. van Nunen, Gosia Lipinska, Dan J. Stein and Edythe D. London. Decision-Making by Patients With Methamphetamine Use Disorder Receiving Contingency Management Treatment: Magnitude and Frequency Effects. *Front. Psychiatry*, 18 February 2020.

We also hosted a guest lecture by Dr. Goodman Sibeko entitled, "Capacitating Non-Specialist Workers in Behavioral Interventions as Part of an HIV Response: Research, Implementation, and Politics". Dr. Sibeko is Head of the Division of Addictions at the University of Cape Town and Co-Director of the South Africa HIV Addiction Technology Transfer Center. His lecture focused on behavioral health and HIV and his efforts to train and utilize non-specialist community health workers in the delivery of mental health care. A recording of his presentation can be found [here](#).



Vietnam

Our work in Vietnam also took a large step forward this year with a new grant awarded by the National Institute on Drug Abuse. This collaboration with Dr. Giang Minh Le of Hanoi Medical University is the culmination of several years of work together. This project, "Screen, Treat and Retain Methamphetamine-Using People with Opioid Use Disorders at MMT Clinics (STAR-OM)", will develop and evaluate optimal combinations of evidence-based interventions to improve HIV outcomes and reduce methamphetamine use among people with opioid use disorder (OUD) who are in methadone maintenance therapy (MMT) in Vietnam. Preliminary work has begun to develop the study measures and we expect to be in the field next year.



Training, Evaluation & Capacity Building

CBAM is dedicated to training future researchers.



At this past year's UCLA Postdoctoral Scholars & Mentors Awards Ceremony, Dr. Shoptaw received a nomination for outstanding mentoring. He is pictured here with his mentees, Drs. David Goodman-Meza, Dilara Uskup, and Michael Li.

CBAM participated again the National Institute on Drug Abuse Summer Research Internship Program, which supports undergraduate students with a focus on increasing underrepresented populations in addiction research. This year, for the first time, we had the pleasure of hosting a UCLA student, Uwaila Omokaro. Uwaila joined us just prior to her third year at UCLA. Uwaila is chair of the UCLA Student Health Advisory Committee. She also volunteers for Homeless Healthcare Los Angeles. Uwaila's summer at CBAM included research trainings, literature reviews and work on a paper about PrEP use and disclosure. Uwaila continues to work with us through the UCLA Student Research Program.



Media

Dr. Shoptaw was interviewed by CBS2/KCAL9 on February 20, 2020 for a segment of *Goldstein Investigates* about recent fentanyl overdose deaths in Los Angeles.



THE Healthy On April 30, Dr. Keith Heinzerling was quoted in an article about rising alcohol sales during the pandemic. Dr. Heinzerling noted that, despite the difficulties individuals face in staying sober, "Avoiding alcohol and drug use will help to keep you and your immune system as healthy as possible to avoid or fight off infections." The article provides specific recommendations for keeping occupied and for getting the support. You can read more [here](#).

Dr. Shoptaw was quoted in an article by German Lopez of [Vox](#) on The Rise in Meth and Cocaine Overdoses.



Our CHIPTS team was also mentioned by KNX Morning News with Dick Helton and Vicky Moore, commenting on our meeting addressing a regional response to End the HIV Epidemic in California. The meeting was held on January 24, 2020.



CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
Financial Statement for Fiscal Year 2019/2020
(July 1, 2019 through June 30, 2020)

	<u>Permanently</u> <u>Restricted</u>	<u>Temporarily</u> <u>Restricted</u>	<u>Unrestricted</u>	<u>Total</u>	<u>FY 2018/2019</u>
INCOME					
Federal Contracts & Grants	\$ 6,532,007	\$ -	\$ -	\$ 6,532,007	\$ 5,858,764
State/Local Contracts & Grants	\$ 9,162	\$ -	\$ -	\$ 9,162	\$ -
Subcontracts	\$ -	\$ -	\$ -	\$ -	\$ -
Corporations	\$ 30,000	\$ -	\$ -	\$ 30,000	\$ 51,236
Foundations	\$ -	\$ -	\$ -	\$ -	\$ 222,237
Individuals	\$ -	\$ -	\$ 4,543	\$ 4,543	\$ -
UC Funds	\$ -	\$ 84,460		\$ 84,460	\$ 164,947
Clinical Services Income	\$ -	\$ -	\$ 165,399	\$ 165,399	\$ 1,173,907
TOTAL INCOME	\$ 6,571,169	\$ 84,460	\$ 169,941	\$ 6,825,570	\$ 7,471,091
EXPENSES					
Academic Salaries				\$ 438,225	\$ 850,081
Staff Salaries				\$ 1,546,299	\$ 1,763,962
Fringe Benefits				\$ 850,229	\$ 1,045,124
Stipends - Postdoctoral Fellows				\$ 6,942	\$ -
Stipends - Interns				\$ 6,840	\$ -
Consultants/Guest Lecturers				\$ 11,372	\$ 32,246
Employee Training/Certifications/Licenses/Memberships				\$ 3,985	\$ 540
Subawards				\$ 192,705	\$ 84,989
Funds Transferred to Other Departments (Direct)				\$ 782,957	\$ 925,608
Space Rental				\$ 173,351	\$ 187,613
Alterations/Renovations				\$ 107	\$ 6,172
Communications				\$ 62,145	\$ 49,680
Clinic Operations				\$ 30,167	\$ 50,586
General Supplies & Equipment				\$ 3,007	\$ 2,088
Computers, Software & Computer Supplies				\$ 12,976	\$ 21,647
Medical Supplies				\$ 20,127	\$ 26,013
Project-Related Supplies				\$ 31,041	\$ 50,408
Travel and Events				\$ 108,997	\$ 146,143
Postage/Courier				\$ 26,666	\$ 39,475
Print/Copy Services				\$ 6,363	\$ 5,957
Publication Fees				\$ 15,000	\$ -
Transcription Services				\$ 1,357	\$ -
Recruitment Ads				\$ 70,468	\$ 128,112
Lab Services				\$ 100,039	\$ 142,533
Pharmacy				\$ 31,644	\$ 52,676
Inpatient Care				\$ 153,397	\$ 112,513
Participant Incentives				\$ 86,027	\$ 142,691
Website Services				\$ 3,758	\$ -
Miscellaneous				\$ 1,726	\$ 1,816
Indirect Charges				\$ 1,265,743	\$ 1,401,173
TOTAL EXPENSES				\$ 6,043,659	\$ 7,269,848
NET INCOME (LOSS) YTD*				\$ 781,911	\$ 201,243

This document was generated internally. It is not an audited financial statement.

**The net balance is primarily restricted project funding that will carryover into the next fiscal year. Spending slowed in the 4th quarter as the pandemic interrupted activities that will resume in the new year.*



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

Show your support!

To help support this life-changing work, visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0645 to speak with our Administrative Director. More than 92% of every donation goes directly to serve our mission and all donations are tax deductible. Naming opportunities are available!

